Nykode Therapeutics Loses kr144m Market Value But Insiders See Windfall Of US$665k
Insiders who bought Nykode Therapeutics AS (OB:NYKD) in the last 12 months may probably not pay attention to the stock's recent 11% drop. Even after accounting for the recent loss, the US$707.4k worth of stock purchased by them is now worth US$1.37m or in other words, their investment continues to give good returns.
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
The Last 12 Months Of Insider Transactions At Nykode Therapeutics
Over the last year, we can see that the biggest insider purchase was by Independent Director Susanne Stuffers for kr507k worth of shares, at about kr1.81 per share. We do like to see buying, but this purchase was made at well below the current price of kr3.59. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.
While Nykode Therapeutics insiders bought shares during the last year, they didn't sell. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
See our latest analysis for Nykode Therapeutics
There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).
Does Nykode Therapeutics Boast High Insider Ownership?
Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our information indicates that Nykode Therapeutics insiders own about kr9.1m worth of shares. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. This level of insider ownership is notably low, and not very encouraging.
So What Do The Nykode Therapeutics Insider Transactions Indicate?
The fact that there have been no Nykode Therapeutics insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Nykode Therapeutics stock. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Nykode Therapeutics. For instance, we've identified 4 warning signs for Nykode Therapeutics (3 are significant) you should be aware of.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.